Dr Reddys Laboratories (RDY) Return on Assets (2009 - 2026)
Dr Reddys Laboratories (RDY) posted quarterly Return on Assets of 0.0% for Q1 2026, little changed year-on-year from 0.0% in Q1 2025, and down 56.64% on a QoQ basis from 0.0% in Q1 2025.
Dr Reddys Laboratories (RDY) Return on Assets (2009 - 2026) Analysis & Trends
Dr Reddys Laboratories (RDY) has reported Return on Assets for 3 consecutive years, with 0.0% the latest figure, recorded in Q1 2026.
- Quarterly Return on Assets changed 0.0% year-over-year to 0.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.0% (changed 0.0% YoY) and the FY2026 annual result came in at 0.0%, changed 0.0% from the prior year.
- Return on Assets declined to 0.0% in Q1 2026 per RDY's latest filing, from 0.0% in the prior quarter.
- Over the last five years, Return on Assets for RDY reached as high as 0.0% in Q1 2025 and fell as low as 0.0% in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROA (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 0.00% |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 0.00% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 0.00% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 0.00% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 0.00% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.00% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 0.00% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 0.00% |
| 10 | Dr Reddys Laboratories | 9.82 Bn | 9.66 Bn | - | 0.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.00% |
| Mar 31, 2025 | 0.00% |
| Dec 31, 2009 | -0.01% |
| Sep 30, 2009 | -0.01% |